Navigation Links
CD-Chex CD34 Leukocyte Control

ProductsCD-Chex CD34 Leukocyte Control
Company Streck
Item CD-Chex CD34 Leukocyte Control
Features 
Description CD-Chex CD34 is a stabilized preparation of human blood leukocytes which can be used as a complete process control when evaluating CD34 positive cells. It is compatible with both ISHAGE and ProCOUNT gating strategies. CD-Chex CD34 has 30-day open-vial stability and 90-day closed-vial stability.
Info Streck
Customer Service: (800) 228-6090
Web site: http://www.streck.com/default.asp

Related medicine products :

1. CD-Chex Plus Immunophenotyping Control
2. CD-Chex Plus BC Immunophenotyping Control
3. Fecal Leukocytes
4. Hexosaminidase A & Total, Leukocytes
5. Leukocyte Alkaline Phosphatase
6. Leukocyte Lysosomal Enzyme
7. Endoalpha Centralized O.R. Control System
8. Cruise Control
9. US Autoflow Single Chamber Stackable Water-Jacketed CO2 Inc.w/ Humidity Display and Control
10. Fluid Control 2203
11. Flow Controller
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 1CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 2CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals 14631 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 1Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 2Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 4Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 14627 5Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 1Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 2Breast Health is a Year Round Priority 3A New Technology Identifies Risk of Breast Cancer in Younger Women 5779 3